Dr. Mesquida Marina

Dr. Mesquida Marina

Uveitis Specialist

Department of Ophthalmology, Hospital Clinic of Barcelona
Barcelona, Spain

plus Speciality

OPHTHALMOLOGY

Biography:

Uveitis and Retina Specialist in the Institut of Ophthalmology, Hospital Clinic of Barcelona.

Academic positions:

ACADEMIC BACKGROUND

1. Medical Doctor: Medical diploma, University of Lleida, Spain (June 2007).
2. Performed the MIR exam in January 2008. Position number 638.
3. Resident of Ophthalmology: Department of Ophthalmology, Hospital Clinic of Barcelona, Barcelona, Spain (May 2008 – May 2012).
4. Current position: Specialty Doctor in Ophthalmology since June 2012 at the Department of Ophthalmology, Hospital Clinic of Barcelona, Barcelona, Spain.
5. Private practice: Ophthalmology Specialist in Barnaclinic since February 2013
6. Teaching: Clinical Professor of Ophthalmology in the Medical Degree of the University of Barcelona since March 2013.

GRANTS AND AWARDS

1. April 2013: “CLINIC-MSD Award 2013”. Best resident of the Hospital Clinic of Barcelona. Grant: 2000 euros.
2. November 2011: “Best investigation project in Ophthalmology of the year 2011” Awarded from the Catalan Society of Ophthalmology for the project entitled Cytokine profile in Behçet’s uveitis. Principal investigator: Marina Mesquida. Grants: 6000 eu
3. July 2011: “Grant for abroad speciality training for residents 2011” Awarded from the Academy of Medical Sciences of Catalonia and Balearic Islands to perform an Observership in Ocular Immunology and Inflammation with Prof. A. Dick in UK. Grant: 1500 eu.
4. November 2009: “Best oral communication of the Congress of the Catatalan Society of Ophthalmology” to Ricardo P Casaroli-Marano, Amanda Rey, Marina Mesquida, et al. Title: Immediate Complications of intravitreal injections with anti-angiogenics after use of a standard operating protocol: a purpose of 1114 consecutive cases.

Research interests:

Uveitis, Behçet's disease, biologic drugs, ocular immunology

Any other information:

PUBLICATIONS

1. Rey A, Molins B, Llorenç V, Mesquida M, Pelegrin L, Adan A. Cytokine Profiling Reveals Decreased Serum Levels Of CCL2 In Active Ocular Toxoplasmosis. Br J Ophthalmol. Accepted 2013
2. Mesquida M, Molins B, Llorenç V, Hernandez MV, Espinosa G, Adan A. Current and future treatments for Behçet’s uveitis. Road to remission. International Ophthalmology. Epub ahead of print.
3. Adan A, Mesquida M, Llorenç V. Update in biological drugs for noninfectious uveitis. Expert Opinion Ophthalmology. Accepted 2013.
4. Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernandez MV, Pelegrin L. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. Accepted 2013.
5. Rey A, Adan A, Llorens V, Pelegrin L, Mesquida M. Late spectral-domain optical coherence tomography findings in sub-internal limiting membrane hemorrhage. Retinal cases & brief reports (In Press)
6. Adan A, Pelegrin L, Rey A, Llorens V, Mesquida M, Molins B, Rios J, Keller J. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina. 2013; 33(7):1435-40.
7. Rey A, Llorenç V, Pelegrin L, Mesquida M, Molins B, Rios J, Arevalo A, Adán A. Clinical pattern of  Toxoplasmic retinochoroiditis in a Spanish referral  center. Ophthalmologica. 2013;229(3):173-8.
8. Llorenç V, Molins B, Rey A, Mesquida M, Adán A. Adalimumab in Serpiginous Choroiditis. Ocul Immunol Inflamm. 2013 Jun;21(3):237-40.
9. Adán A, Llorenç V, Mesquida M, Pelegrín L. Tocilizumab treatment for recalcitrant uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012 Dec 28. [Epub ahead of print]
10. Mesquida M Md, Victoria Hernández M Md Phd, Llorenç V Md, Pelegrín L Md Phd, Espinosa G Md Phd, Dick AD Md Fmed Sci, Adán A Md Phd. Behçet Disease-associated Uveitis Successfully Treated with Golimumab. Ocul Immunol Inflamm. 2013 Apr;21(2):160-2.
11. Mesquida M, Pelegrín L, Llorenç V, Espinosa G, Ríos J, Dick AD, Adán A. Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis. Eur J Ophthalmol. 2012 Sep 26:0. doi: 10.5301/ejo.5000194. [Epub ahead of print]
12. Llorenç V, González-Martin J, Keller J, Rey A, Pelegrín L, Mesquida M, Adán A. Indirect supportive evidence for diagnosis of tuberculosis-related uveitis: from the tuberculin skin test to the new interferon gamma release assays. Acta Ophthalmol. 2013 Mar;91(2):e99-e107.
13. Mesquida M, Llorenç V, Cervera C, Adán A. Ocular brucellosis. Med Clin (Barc). 2013 Mar 16;140(6):284. doi: 10.1016/j.medcli.2012.07.008.
14. Llorenç V, Rey A, Mesquida M, Pelegrín L, Adán A. Central nervous system demyelinating disease-associated uveitis. Arch Soc Esp Oftalmol. 2012 Oct;87(10):324-9. doi: 10.1016/j.oftal.2012.04.027.
15. Perra D, Alba MA, Callejas JL, Mesquida M, Ríos-Fernández R, Adán A, Ortego N, Cervera R, Espinosa G.Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford). 2012 Oct;51(10):1825-31.
16. Pelegrín L, Mesquida M, Rey A, Sánchez-Dalmau B, Frohman L. Blind runner. Surv Ophthalmol. 2012 Sep;57(5):486-94. doi: 10.1016/j.survophthal.2011.06.004.
17. Llorenç Bellés V, Adán Civera A, Espinosa Garriga G, Cervera Segura R, González Martínez J, Pelegrín Colás L, Keller J, Rey Torrente A, Mesquida Febrer M. Uveitis diagnosis characterization at a referral centre in the area of Barcelona, Spain. Med Clin (Barc). 2012 Mar 24;138(7):277-82.
18. Pelegrín L, Mesquida M, Adán A, Cervera C, Bosch-Mestres J, Esteban-Redondo C, Juiz-González P, Llorenç V, Miró JM. Candida dubliniensis endophthalmitis in a HIV-infected intravenous drug abuser. Mycoses. 2011 Nov;54(6):e856-8.
19. Mesquida M, Pelegrín L, Lopez M, Ortiz-Perez S, Sanchez-Dalmau B. Bilateral optic neuropathy related to tacrolimus toxicity. Neuro-ophthalmology. 2011;35(1):S51. ISSN:0165-8107.
20. Mesquida M, Sanchez-Dalmau B, Pelegrín L, Adán A, López L. Oxaliplatin Ocular Toxicity. Neuro-ophthalmology. 2011;35(1):S50. ISSN:0165-8107.

What I think of the idea behind WebmedCentral and WebmedCentral plus:

Good new project